Open AccessHigher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection
Author(s) -
Lillian Seu,
Gabriel M. Ortiz,
Lorrie Epling,
Elizabeth Sinclair,
Louise Swainson,
Urmila D. Bajpai,
Yong Huang,
Steven G. Deeks,
Peter W. Hunt,
Jeffrey N. Martin,
Joseph M. McCune
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0084091
Subject(s) - interquartile range , cd8 , antiretroviral therapy , medicine , t cell , cd4 t cell , immunology , immune system , cytotoxic t cell , gastroenterology , cd4 cd8 ratio , human immunodeficiency virus (hiv) , viral load , lymphocyte subsets , biology , in vitro , biochemistry
HIV-mediated immune dysfunction may influence CD4 + T cell recovery during suppressive antiretroviral therapy (ART). We analyzed cellular biomarkers of immunological inflammation, maturation, and senescence in HIV-infected subjects on early suppressive ART. We performed longitudinal analyses of peripheral immunological biomarkers of subjects on suppressive ART (n = 24) from early treatment (median 6.4 months, interquartile range [IQR] 4.8–13.9 months) to 1–2 years of follow-up (median 19.8 months, IQR 18.3–24.6 months). We performed multivariate regression to determine which biomarkers were associated with and/or predictive of CD4 + T cell recovery. After adjusting for the pre-ART CD4 + T cell count, age, proximal CD4 + T cell count, and length of ART medication, the percentage of CD27 + CD8 + T cells remained significantly associated with the CD4 + T cell recovery rate (β = 0.092 cells/ul/month, P = 0.028). In HIV-infected subjects starting suppressive ART, patients with the highest percentage of CD8 + T cells expressing CD27 had the greatest rate of CD4 + T cell recovery.